DDDD Chief Scientific Officer: If MRx-4DP0004 is successful in this study it would represent a highly significant breakthrough in the global fight against the novel coronavirus pandemic." Let's hope this indeed proves to be a life saver for all those unfortunate to contract this virus.
Current evidence suggests a reason for the high mortality rate of COVID-19 may be due to the hyper-inflammatory response and cytokine storm syndrome caused by uncontrolled activation of the immune system. There is an urgent need for a safe and effective therapy to prevent and treat the severe inflammatory symptoms of COVID-19, to alleviate the significant burden on hospitals and intensive care units (ICUs).Targeted immunomodulation may be beneficial in these patients.
"Over the last month we have worked intensively with our clinical collaborators and the regulatory agencies to accelerate the assessment of MRx-4DP0004 in COVID-19 patients. Clearly this is a fast moving and rapidly developing situation. As an integrated company we have manufacturing capability to provide drug and our key focus over the coming weeks will be initiating the trial as soon as possible. If MRx-4DP0004 is successful in this study it would represent a highly significant breakthrough in the global fight against the novel coronavirus pandemic."